MST1 and diabetes mellitus: In addition, MST1 inhibition by another pharmacological inhibitor (XMU-MP-1) demonstrated potential benefit in diseases beyond diabetes, for example, inflammatory bowel disease (IBD), liver injury9, and heart failure10 via enhanced tissue repair and regeneration.